Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2025

Park Sehhoon, Ahn Hee Kyung, Lee Seoyoung, Min Young Joo, Kim Jinyong, Jung Hyun Ae, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Ahn Myung-Ju, Lee Jii Bum, Lim Sun Min, Kim Hye Ryun, Cho Byoung Chul, Hong Min Hee

Abstract excerpt

INTRODUCTION: Uncommon EGFR mutations comprise 10% to 20% of all EGFR mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common EGFR mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib in patients with NSCLC with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Morpholines

Share to Pyrazoles

Share to Pyrimidines

Share to Survival Rate

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 40350080
DOI: 10.1016/j.jtho.2025.05.006

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.PMID 40350080Read ↗

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.Semantic proximity Read ↗

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.Semantic proximity Read ↗

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).Semantic proximity Read ↗

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).Semantic proximity Read ↗

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.Semantic proximity Read ↗

Current management of uncommon EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Uncommon EGFR mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.Semantic proximity Read ↗

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical NeedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.